Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) EBITDA Margin (2021)

Historic EBITDA Margin for Atea Pharmaceuticals (AVIR) over the last 1 years, with Q4 2021 value amounting to 60.95%.

  • Atea Pharmaceuticals' EBITDA Margin changed N/A to 60.95% in Q4 2021 from the same period last year, while for Sep 2022 it was 18.11%, marking a year-over-year decrease of 18700.0%. This contributed to the annual value of 34.49% for FY2021, which is 570000.0% up from last year.
  • According to the latest figures from Q4 2021, Atea Pharmaceuticals' EBITDA Margin is 60.95%.
  • Atea Pharmaceuticals' 5-year EBITDA Margin high stood at 60.95% for Q4 2021, and its period low was 85.93% during Q3 2021.